Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 0.97B P/E - EPS this Y -9.40% Ern Qtrly Grth -
Income -83.99M Forward P/E 5.60 EPS next Y 13.80% 50D Avg Chg 13.00%
Sales 2.39B PEG -6.78 EPS past 5Y 7.32% 200D Avg Chg 43.00%
Dividend N/A Price/Book 1.66 EPS next 5Y -1.50% 52W High Chg -14.00%
Recommedations 2.20 Quick Ratio 0.87 Shares Outstanding 308.55M 52W Low Chg 157.00%
Insider Own 55.79% ROA 4.67% Shares Float 135.69M Beta 1.35
Inst Own 29.16% ROE -36.06% Shares Shorted/Prior 2.80M/2.07M Price 3.19
Gross Margin 36.09% Profit Margin -3.51% Avg. Volume 1,023,872 Target Price 7.25
Oper. Margin 13.19% Earnings Date Feb 29 Volume 619,744 Change 0.63%
About Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Amneal Pharmaceuticals, Inc. News
04/24/24 Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose
04/16/24 Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine
04/15/24 Amneal Pharmaceuticals (NASDAQ:AMRX) shareholders are still up 235% over 1 year despite pulling back 8.0% in the past week
04/10/24 Amneal to Report First Quarter 2024 Results on May 3, 2024
03/28/24 Amneal to Ring the Nasdaq Closing Bell on April 2, 2024
03/25/24 Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
03/01/24 Amneal Pharmaceuticals Inc (AMRX) Reports Mixed 2023 Financial Results
03/01/24 Amneal Reports Fourth Quarter and Full Year 2023 Financial Results
02/27/24 Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203
02/18/24 Insiders the biggest winners as Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) market cap rises to US$1.8b
02/13/24 Amneal to Participate at Upcoming Investor Conference
02/08/24 Amneal Announces Complete Response Resubmission for IPX203 New Drug Application
01/31/24 Amneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024
01/25/24 Knight Therapeutics Enters into Exclusive License Agreement with Amneal Pharmaceuticals for IPX203
01/10/24 Amneal Launches Complex Generic Fluorometholone Ophthalmic Suspension
01/04/24 Amneal Launched Record Number of 39 New Retail and Injectable Products in 2023, Including 13 in Q4 2023
12/21/23 Amneal to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
12/15/23 Amneal Announces Move to Nasdaq
12/07/23 Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)
12/01/23 Amneal Expands Portfolio with Addition of Icosapent Ethyl Acid Soft Gel Capsules
AMRX Chatroom

User Image DaBigCheese5000 Posted - 1 day ago

$AMRX volume increasing, double bottom forming.. time to load..

User Image StocksWithFlav Posted - 1 day ago

Some charts to keep an eye on today $NCI $AMRX $META $LASE $ABVC

User Image Cousin_Vinny Posted - 2 days ago

$AMRX #opioid #abuse #FDA

User Image Gostrongx Posted - 2 days ago

$AMRX up 10% ? What is happening here. Anyone ?

User Image nina3 Posted - 2 days ago

$AMRX needs volume

User Image tommytwit Posted - 2 days ago

$AMRX Surprised this isn't higher by now

User Image StocksWithFlav Posted - 2 days ago

$ANIX KEEP AN EYE ON THIS NAME GETTING SOME HITS - TRADING NEAR SUPPORT / COULD EXPECT A BOUNCE - FLOAT ~30M - 0 DEBT - 24M CASH & CASH EQUIVALENTS - EXTENSIVE PIPELINE WITH NEAR TERM CATALYST - RECENT INSIDER BUYING Recent insider buying http://insiderbuyingselling.com/?t=ANIX $HOOK $AMRX $DAWN $ABVC

User Image tradingtwenty Posted - 2 days ago

$AMRX has trended 6 times in the past 24 hours (based on 5 minute intervals). Latest press release on Apr 24, 2024 08:00 AM: Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment... Link: https://tradingtwenty.com/news/441177/amneal-announces-us-fda-approval-of-over-the-counter-naloxone-hydrochloride-nasal-spray-for-emergency-treatment-of-an-opioid-overdose

User Image StocksWithFlav Posted - 2 days ago

Some setups to keep on radar into open $NKGN $AGBA $ANIX $AMRX $HOOK

User Image HorsePicks Posted - 2 days ago

$AMRX) (“Amneal” or the “Company”) today announced the availability of Over the Counter (“OTC”) Naloxone Hydrochloride (Naloxone HCI) Nasal Spray, USP, 4mg, following Abbreviated New Drug Application (“ANDA”) approval from the U.S. Food and Drug Administration (“FDA”).

User Image winners234 Posted - 2 days ago

$AMRX

User Image Stock_Titan Posted - 2 days ago

$AMRX Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose https://www.stocktitan.net/news/AMRX/amneal-announces-u-s-fda-approval-of-over-the-counter-naloxone-fic43966u6iu.html

User Image StockInvest_us Posted - 2 days ago

Signal alert: $AMRX - Oversold Trend Short (Undervalued) https://stockinvest.us/l/qwjPImPmZ0

User Image Gostrongx Posted - 3 days ago

$AMRX What ever happens with IPX203? Should be discussed on the confcall. AMRX needs to elevate itself from being just a generic

User Image burke1 Posted - 4 days ago

$AMRX wait till earnings.

User Image Gostrongx Posted - 4 days ago

$AMRX this is going in the wrong direction again!

User Image StockInvest_us Posted - 6 days ago

Signal alert: $AMRX - Oversold Trend Short (Undervalued) https://stockinvest.us/l/VvuHJufB7g

User Image Aigner_Andreas Posted - 6 days ago

TD BUY $AMRX at 5.42, Supp 5.36 Resis 6.12 R14 HiLo 80% T1Y 5 buy 2.4 DIV N/A #Amneal Pha #stocks #trading #finance #market

User Image burke1 Posted - 1 week ago

$AMRX what he has to do with anything. He is nobody

User Image bertbertybert Posted - 1 week ago

$AMRX he speaking late July

User Image burke1 Posted - 1 week ago

$AMRX look at option market. There is over 3500 call for 7.50 traded today for may. Someone thinking this is way going to be up after earnings.

User Image Gostrongx Posted - 1 week ago

$AMRX when does the run up to earnings start? The previous qtrs have been good

User Image Stock_Titan Posted - 1 week ago

$AMRX Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine https://www.stocktitan.net/news/AMRX/amneal-launches-pemrydi-rtu-r-the-first-ready-to-use-version-of-kjraoj8mkg8a.html

User Image Stock_Titan Posted - 2 weeks ago

$AMRX Amneal to Report First Quarter 2024 Results on May 3, 2024 https://www.stocktitan.net/news/AMRX/amneal-to-report-first-quarter-2024-results-on-may-3-kem8fti4brsz.html

User Image Gostrongx Posted - 2 weeks ago

$AMRX up 20% premarket. What’s happening?

User Image DonCorleone77 Posted - 2 weeks ago

$BHC $BLCO $AMRX Bausch suit creates added uncertainty on B+L spin, says TD Cowen After Bausch Health (BHC) along with its gastroenterology unit Salix Pharmaceuticals announced that it filed a lawsuit against Amneal Pharmaceuticals (AMRX), TD Cowen analyst Michael Nedelcovych said this lawsuit "appears to have restarted the clock on months or years' worth of litigation" that must be settled to ensure Xifaxan's outlook. Since certainty around Xifaxan is critical to the financial health of the Bausch "remainco," this news would seem to further jeopardize, or at least delay, a Bausch + Lomb (BLCO) share distribution, contends the analyst, who keeps a Hold rating on Bausch Health shares.

User Image DonCorleone77 Posted - 2 weeks ago

$BHC $AMRX Bausch Health files patent lawsuit against Amneal Pharmaceuticals Bausch Health Companies (BHC) along with its gastroenterology business, Salix Pharmaceuticals, announced that it filed a lawsuit in the United States District Court for the District of New Jersey against Amneal Pharmaceuticals (AMRX) of New York, Amneal EU, Limited, Amneal Pharmaceuticals, Amneal Pharmaceuticals Private Limited, and Amneal Pharmaceuticals. This lawsuit follows receipt of a Notice of Paragraph IV Certification stating that Amneal submitted an Abbreviated New Drug Application to the U.S. FDA seeking approval to market a generic version of XIFAXAN 550 mg tablets. Amneal asserts that certain patents listed in the FDA's Orange Book for XIFAXAN are unenforceable, invalid, and/or not infringed by Amneal's ANDA product. This action formally initiates the litigation process under the Hatch-Waxman Act and triggers a 30-month stay of any potential FDA approval for Amneal's ANDA.

User Image burke1 Posted - 3 weeks ago

$AMRX what happen I am watching them close the bell and I don’t see them. ? Are they not supposed to ring bell at nadaq?

User Image Gostrongx Posted - 3 weeks ago

$AMRX midday dump! What happened cmon Chirags

User Image Stock_Titan Posted - 03/28/24

$AMRX Amneal to Ring the Nasdaq Closing Bell on April 2, 2024 https://www.stocktitan.net/news/AMRX/amneal-to-ring-the-nasdaq-closing-bell-on-april-2-9n9i61uigx84.html

Analyst Ratings
Piper Sandler Overweight Mar 21, 24
Goldman Sachs Buy Mar 4, 24
Barclays Overweight Jan 29, 24
Truist Securities Buy Nov 8, 23
Truist Securities Buy Sep 6, 23
Piper Sandler Overweight Aug 7, 23
Truist Securities Buy Aug 7, 23
Barclays Overweight Aug 7, 23
Piper Sandler Overweight May 8, 23